Today, on International Day of Women and Girls in Science, we shine a spotlight on the incredible women who push the boundaries of science and healthcare. Hear from one of our own team members about the importance of fostering a love of science in women and girls. “I believe that early introduction to scientific concepts is vital for continued curiosity in the many STEM fields. That’s why my favorite part of being a woman in science is teaching future scientists about the world around them and watching that inquisitiveness grow. Whether it be in my college classroom or in my kindergartener’s classroom, one of the most important things I can impart on the next generation is that this is a viable career path for anyone if that’s where their heart lies.” – Keri Wyllie, MPA, Director of Preclinical Operations Learn more: https://lnkd.in/deiWnvHv #womeninscience #womeninstem
Codagenix Inc.
生物技术研究
Farmingdale，New York 2,635 位关注者
Design Platform for Vaccine & Oncolytic Virus development ~ COVID, Flu, RSV, Dengue, YF / Breast Cancer & Solid Tumors.
关于我们
Codagenix Inc. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development. Codagenix uses a computer-based algorithm, called SAVE (Synthetic Attenuated Virus Engineering) to design viral genomes that are identical to the wild type strain at the amino acid level, but make less protein in human cells. The highly attenuated viruses make excellent vaccines or oncolytics against solid tumors. Codagenix represents the next wave in vaccine technology, untethered from traditional, time-consuming and unpredictable approaches to attenuating viruses.
- 网站
-
https://www.codagenix.com
Codagenix Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Farmingdale，New York
- 类型
- 私人持股
- 创立
- 2011
- 领域
- Live-attenuated vaccine design、infectious disease、Synthetic biology、virology、clinical trials、vaccines、influenza、RSV、dengue和oncolytics
地点
-
主要
获取路线
3 Bioscience Park Dr
US，New York，Farmingdale，11735
Codagenix Inc.员工
动态
-
Dr. Jeffrey Fu, Chief Business Officer at Codagenix, describes the characteristics needed in next-generation COVID vaccines. At Codagenix, our vaccine program strives address these factors as a live-attenuated, intranasal vaccine that induces an antibody and cell-mediated immunity (CMI). Learn more: https://www.codagenix.com
-
-
Did you know? RSV poses a significant risk to children; the virus hospitalizes up to 80,000 and annually in the U.S. and >80% of RSV-associated lower respiratory infections and more than half of RSV deaths occur in children ages 6 months and older. At Codagenix, we are developing an intranasal RSV vaccine that will easily integrate into the routine childhood vaccine schedule. Learn more: https://www.codagenix.com
-